DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness
A Randomized, Double-Blind Placebo-Controlled Phase 3 Study of the Safety, Pharmacokinetics, and Efficacy of DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness
Sponsor: Repurposed Therapeutics, Inc.
Terminated
Failure to meet enrollment
Other terminated trials from Repurposed Therapeutics, Inc.
More terminations from Repurposed Therapeutics, Inc.
Listed as NCT04219982, this PHASE2/PHASE3 trial focuses on Motion Sickness and remains terminated or withdrawn. Sponsored by Repurposed Therapeutics, Inc., it has been updated 4 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
First recorded
Jun 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Repurposed Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .